接受二甲双胍、SGLT-2抑制剂或二者联合治疗的2型糖尿病患者患结直肠癌及癌症相关死亡率的风险 - Suppr

Risk of colorectal cancer and cancer-related mortality in type 2 diabetes patients treated with metformin, SGLT-2 inhibitors, or their combination.

作者信息

Mao Xianhua, Cheung Ka-Shing, Tan Jing-Tong, Mak Lung-Yi, Lee Chi-Ho, Cheng Ho Ming, Hui Rex Wan-Hin, Chan Esther Wai Yin, Yu Philip Leung-Ho, Yuen Man-Fung, Leung Wai K, Seto Wai-Kay

机构信息

Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong, P. R. China.

Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong, P. R. China.

出版信息

Cancer Commun (Lond). 2025 Jul;45(7):880-883. doi: 10.1002/cac2.70028. Epub 2025 Apr 24.

DOI:10.1002/cac2.70028

PMID:40275591

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12328085/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecc2/12328085/07c723311afa/CAC2-45-880-g001.jpg

相似文献

Risk of colorectal cancer and cancer-related mortality in type 2 diabetes patients treated with metformin, SGLT-2 inhibitors, or their combination.接受二甲双胍、SGLT-2抑制剂或二者联合治疗的2型糖尿病患者患结直肠癌及癌症相关死亡率的风险

Cancer Commun (Lond). 2025 Jul;45(7):880-883. doi: 10.1002/cac2.70028. Epub 2025 Apr 24.

Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: systematic review and meta-analyses.二甲双胍与钠-葡萄糖共转运蛋白抑制剂联合治疗 2 型糖尿病的疗效：系统评价和荟萃分析。

Diabetes Res Clin Pract. 2014 Sep;105(3):313-21. doi: 10.1016/j.diabres.2014.06.006. Epub 2014 Jun 22.

SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline.钠-葡萄糖协同转运蛋白 2 抑制剂或胰高血糖素样肽-1 受体激动剂治疗 2 型糖尿病成人患者：临床实践指南。

BMJ. 2021 May 11;373:n1091. doi: 10.1136/bmj.n1091.

GLUcose COntrol Safety & Efficacy in type 2 DIabetes, a systematic review and NETwork meta-analysis.2 型糖尿病血糖控制安全性和疗效的系统评价和网络荟萃分析。

PLoS One. 2019 Jun 25;14(6):e0217701. doi: 10.1371/journal.pone.0217701. eCollection 2019.

Comparative efficacy of GLP-1 RAs/SGLT-2 inhibitors in reducing cardiovascular events in type 2 diabetes according to baseline use of metformin: a systematic review and meta-analysis of randomized controlled trials.根据二甲双胍的基线使用情况比较胰高血糖素样肽-1受体激动剂/钠-葡萄糖协同转运蛋白2抑制剂在降低2型糖尿病患者心血管事件方面的疗效：一项随机对照试验的系统评价和荟萃分析

Eur J Med Res. 2025 Jan 7;30(1):13. doi: 10.1186/s40001-024-02241-4.

The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.二肽基肽酶-4（DPP-4）抑制剂或钠-葡萄糖共转运蛋白 2（SGLT-2）抑制剂联合二甲双胍治疗 2 型糖尿病患者的安全性：系统评价和荟萃分析。

Diabetes Metab Res Rev. 2014 May;30(4):269-83. doi: 10.1002/dmrr.2494.

Comparative efficacy of once-weekly semaglutide and SGLT-2 inhibitors in type 2 diabetic patients inadequately controlled with metformin monotherapy: a systematic literature review and network meta-analysis.每周一次司美格鲁肽与 SGLT-2 抑制剂在二甲双胍单药治疗控制不佳的 2 型糖尿病患者中的疗效比较：系统文献回顾和网络荟萃分析。

Curr Med Res Opin. 2018 Sep;34(9):1595-1603. doi: 10.1080/03007995.2018.1476332. Epub 2018 May 29.

Incretin mimetics and sodium-glucose co-transporter 2 inhibitors as monotherapy or add-on to metformin for treatment of type 2 diabetes: a systematic review and network meta-analysis.肠促胰岛素类似物和钠-葡萄糖共转运蛋白 2 抑制剂作为单药治疗或与二甲双胍联合治疗 2 型糖尿病：系统评价和网络荟萃分析。

Acta Diabetol. 2021 Jan;58(1):5-18. doi: 10.1007/s00592-020-01542-4. Epub 2020 Jun 8.

Sodium-glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.钠-葡萄糖协同转运蛋白（SGLT）2抑制剂用于预防或延缓2型糖尿病高危人群发生2型糖尿病及其相关并发症。

Cochrane Database Syst Rev. 2016 Apr 21;4(4):CD012106. doi: 10.1002/14651858.CD012106.pub2.

Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.钠-葡萄糖共转运蛋白 2 抑制剂与二肽基肽酶-4 抑制剂单用或与二甲双胍联用治疗 2 型糖尿病患者的疗效和安全性：系统评价和荟萃分析。

Diabetes Obes Metab. 2018 Jan;20(1):113-120. doi: 10.1111/dom.13047. Epub 2017 Aug 10.

本文引用的文献

Optimal glycaemic control and the reduced risk of colorectal adenoma and cancer in patients with diabetes: a population-based cohort study.糖尿病患者的最佳血糖控制与结直肠腺瘤和癌症风险降低：基于人群的队列研究。

Gut. 2024 Jul 11;73(8):1313-1320. doi: 10.1136/gutjnl-2023-331701.

Comparison between sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors on the risk of incident cancer in patients with diabetes mellitus: A real-world evidence study.钠-葡萄糖共转运蛋白 2 抑制剂与二肽基肽酶 4 抑制剂在糖尿病患者新发癌症风险中的比较：一项真实世界证据研究。

Diabetes Metab Res Rev. 2024 Mar;40(3):e3784. doi: 10.1002/dmrr.3784.

Type 2 Diabetes and Colorectal Cancer Risk.2 型糖尿病与结直肠癌风险。

JAMA Netw Open. 2023 Nov 1;6(11):e2343333. doi: 10.1001/jamanetworkopen.2023.43333.

Mapping the metabolic reprogramming induced by sodium-glucose cotransporter 2 inhibition.绘制钠-葡萄糖共转运蛋白 2 抑制诱导的代谢重编程图谱。

JCI Insight. 2023 Apr 10;8(7):e164296. doi: 10.1172/jci.insight.164296.

Lower risks of incident colorectal cancer in SGLT2i users compared to DPP4i users: A propensity score-matched study with competing risk analysis.与二肽基肽酶-4抑制剂（DPP4i）使用者相比，钠-葡萄糖协同转运蛋白2抑制剂（SGLT2i）使用者发生结直肠癌的风险更低：一项采用竞争风险分析的倾向评分匹配研究。

Eur J Intern Med. 2023 Apr;110:125-127. doi: 10.1016/j.ejim.2023.01.021. Epub 2023 Jan 31.

SGLT-2 Inhibitors in Cancer Treatment-Mechanisms of Action and Emerging New Perspectives.SGLT-2抑制剂在癌症治疗中的作用机制及新出现的观点

Cancers (Basel). 2022 Nov 25;14(23):5811. doi: 10.3390/cancers14235811.

AGA Clinical Practice Update on Chemoprevention for Colorectal Neoplasia: Expert Review.AGA 临床实践更新：结直肠肿瘤的化学预防：专家评论。

Clin Gastroenterol Hepatol. 2021 Jul;19(7):1327-1336. doi: 10.1016/j.cgh.2021.02.014. Epub 2021 Feb 10.

Dapagliflozin Inhibits Cell Adhesion to Collagen I and IV and Increases Ectodomain Proteolytic Cleavage of DDR1 by Increasing ADAM10 Activity.达格列净抑制细胞黏附至 I 型胶原和 IV 型胶原，并通过增加 ADAM10 活性增加 DDR1 的胞外结构域蛋白水解切割。

Molecules. 2020 Jan 23;25(3):495. doi: 10.3390/molecules25030495.

Colorectal cancer.结直肠癌。

Lancet. 2019 Oct 19;394(10207):1467-1480. doi: 10.1016/S0140-6736(19)32319-0.

Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials.口服降糖药物治疗的恶性肿瘤的经验在 ADOPT（糖尿病结局进展试验）和 RECORD（罗格列酮心血管评估和糖尿病血糖调节试验）临床试验中随机对照。

Diabetologia. 2010 Sep;53(9):1838-45. doi: 10.1007/s00125-010-1804-y. Epub 2010 Jun 8.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Risk of colorectal cancer and cancer-related mortality in type 2 diabetes patients treated with metformin, SGLT-2 inhibitors, or their combination.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

本文引用的文献